

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

**Date: 14<sup>th</sup> August, 2023**

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited (DCS/Compliance)</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
---	--

**Subject: Outcome of Board Meeting held on Monday 14<sup>th</sup> August, 2023 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Reference: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

With reference to the above captioned subject, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 02/2023-24) held today i.e., Monday, 14<sup>th</sup> day of August, 2023, has inter alia, transacted following matters along with other routine businesses:

1. Approval of un-audited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2023 along with Limited Review Report thereon. ***Copy of results being submitted separately.***
2. Approval of Boards' Report on the operation of the Company along with required annexure and Corporate Governance Report and Management Discussion and Analysis Report for the year ended on 31<sup>st</sup> March, 2023.
3. Approval of appointment of Smt. Gayatri Padiyar (DIN: 10260173) as an Additional Director under the category of Non-Executive Independent Director of the Company for a period of 5 years w.e.f. 14<sup>th</sup> August, 2023 subject to the approval of members in ensuing Annual General Meeting.
4. Re-appointment of Shri Ketan Shah (DIN: 08818212) as Whole Time Director of the Company for a period of three years w.e.f. 25<sup>th</sup> August, 2023 subject to approval of members in ensuing Annual General Meeting.

In compliance to the Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 issued by BSE and Circular No. NSE/CML/2018/24 dated June 20, 2018 issued by NSE, we

confirm that Smt. Gayatri Padiyar (DIN: 10260173), has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority.

Further, continuous disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with reference to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023 is being filed separately with reference to appointment of Independent Director and re-appointment of Whole-Time Director of the Company.

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 06:00 P.M.

This is for your information and record.

Thanking you.

Yours Faithfully,

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**SHWETA VERMA**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO. A70184**